PURPOSE: An unbiased approach of drug discovery through high-throughput screening (HTS) of libraries of chemically defined and bioactive small molecule compounds was used to identify modulators of radiation injury with an emphasis on radioprotectors and mitigators rather than radiosensitisers. Assay system endpoints included radiation-induced genotoxicity and DNA damage in yeast and apoptosis in murine lymphocytes. Large-scale data mining of chemically diverse libraries identified agents that were effective with all endpoints. HTS of bioactive compound libraries against murine lymphocytes profiled tetracycline and fluoroquinolone antibiotics and cyclopiazonic acid as having activity, and structure-activity analysis showed a common pharmacophore. Purine nucleosides, the interferon inducer tilorone, and linoleic acid were also identified as potential mitigators of radiation damage that often were also radioprotective. Many of these compounds enhance DNA repair, have anti-inflammatory activity, and stimulate hematopoiesis. Selected compounds within these initial verified hits from both types of libraries identified potent mitigators of lethal whole body irradiation (WBI) in mice. CONCLUSION: In spite of the fact that in vitro HTS has limitations and is unable to fully recapitulate all aspects of the complex in vivo acute radiation response, it identified several classes of molecules that had activity as radioprotectors and radiomitigators of the hematopoietic system in vivo. In the future, addition of 3-dimensional (3-D) or stem cell cultures or pathway analysis, may improve the power of HTS, but our findings indicate that common, evolutionary conserved, canonical pathways can be identified that could be exploited to mitigate radiation-induced defects.
PURPOSE: An unbiased approach of drug discovery through high-throughput screening (HTS) of libraries of chemically defined and bioactive small molecule compounds was used to identify modulators of radiation injury with an emphasis on radioprotectors and mitigators rather than radiosensitisers. Assay system endpoints included radiation-induced genotoxicity and DNA damage in yeast and apoptosis in murine lymphocytes. Large-scale data mining of chemically diverse libraries identified agents that were effective with all endpoints. HTS of bioactive compound libraries against murine lymphocytes profiled tetracycline and fluoroquinolone antibiotics and cyclopiazonic acid as having activity, and structure-activity analysis showed a common pharmacophore. Purine nucleosides, the interferon inducer tilorone, and linoleic acid were also identified as potential mitigators of radiation damage that often were also radioprotective. Many of these compounds enhance DNA repair, have anti-inflammatory activity, and stimulate hematopoiesis. Selected compounds within these initial verified hits from both types of libraries identified potent mitigators of lethal whole body irradiation (WBI) in mice. CONCLUSION: In spite of the fact that in vitro HTS has limitations and is unable to fully recapitulate all aspects of the complex in vivo acute radiation response, it identified several classes of molecules that had activity as radioprotectors and radiomitigators of the hematopoietic system in vivo. In the future, addition of 3-dimensional (3-D) or stem cell cultures or pathway analysis, may improve the power of HTS, but our findings indicate that common, evolutionary conserved, canonical pathways can be identified that could be exploited to mitigate radiation-induced defects.
Authors: Michael W Epperly; Darcy Franicola; Donna Shields; Jean-Claude Rwigema; Brandon Stone; Xichen Zhang; William McBride; George Georges; Peter Wipf; Joel S Greenberger Journal: In Vivo Date: 2010 Jan-Feb Impact factor: 2.155
Authors: Brian E Lally; Geoffrey A Geiger; Steven Kridel; Alice E Arcury-Quandt; Michael E Robbins; Nancy D Kock; Kenneth Wheeler; Prakash Peddi; Alexandros Georgakilas; Gary D Kao; Constantinos Koumenis Journal: Cancer Res Date: 2007-09-15 Impact factor: 12.701
Authors: Xiaoxia Zhou; Liping Luo; Waike Dressel; Gulibahaer Shadier; Doreen Krumbiegel; Peter Schmidtke; Fred Zepp; Claudius U Meyer Journal: Am J Chin Med Date: 2008 Impact factor: 4.667
Authors: Joo Y Lee; Anthony Plakidas; Won H Lee; Anne Heikkinen; Prithiva Chanmugam; George Bray; Daniel H Hwang Journal: J Lipid Res Date: 2002-12-01 Impact factor: 5.922
Authors: R Yahyapour; E Motevaseli; A Rezaeyan; H Abdollahi; B Farhood; M Cheki; S Rezapoor; D Shabeeb; A E Musa; M Najafi; V Villa Journal: Clin Transl Oncol Date: 2018-01-09 Impact factor: 3.405
Authors: David J Brenner; Nelson J Chao; Joel S Greenberger; Chandan Guha; William H McBride; Harold M Swartz; Jacqueline P Williams Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-01 Impact factor: 7.038
Authors: Sean Ekins; Mary A Lingerfelt; Jason E Comer; Alexander N Freiberg; Jon C Mirsalis; Kathleen O'Loughlin; Anush Harutyunyan; Claire McFarlane; Carol E Green; Peter B Madrid Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo Journal: Radiat Res Date: 2021-01-01 Impact factor: 2.841
Authors: Zachary D Nagel; Carrie M Margulies; Isaac A Chaim; Siobhan K McRee; Patrizia Mazzucato; Anwaar Ahmad; Ryan P Abo; Vincent L Butty; Anthony L Forget; Leona D Samson Journal: Proc Natl Acad Sci U S A Date: 2014-04-22 Impact factor: 11.205
Authors: Elizabeth R Sharlow; Stephanie Leimgruber; Ana Lira; Michael J McConnell; Andrés Norambuena; George S Bloom; Michael W Epperly; Joel S Greenberger; John S Lazo Journal: ACS Chem Biol Date: 2016-03-14 Impact factor: 5.100